In situ expression of messenger RNA of interleukin-1 and interleukin-6 in psoriasis: interleukin-6 involved in formation of psoriatic lesions - PubMed (original) (raw)

In situ expression of messenger RNA of interleukin-1 and interleukin-6 in psoriasis: interleukin-6 involved in formation of psoriatic lesions

Y Ohta et al. Arch Dermatol Res. 1991.

Abstract

Psoriasis is a disease of abnormal proliferation and differentiation of epidermal cells. Several cytokines released by keratinocytes are implicated as factors responsible for this pathological condition of the epidermis. In order to elucidate the role of these cytokines in psoriasis, messenger RNA (mRNA) expression of interleukin-1 (IL-1) and IL-6 in psoriatic epidermis was investigated using biotin-labelled complementary DNA (cDNA) of the cytokines. Messenger RNA of IL-1 alpha was weakly detected in some normal healthy epidermis specimens and more strongly in all the perilesional uninvolved psoriatic epidermis specimens. It was also expressed in the transitional zone between uninvolved and fully developed psoriatic skin, but was not expressed in lesional skin. In contrast, IL-6 mRNA was rarely expressed in normal healthy epidermis, but was expressed in perilesional uninvolved psoriatic epidermis, in the transitional zone and in the fully developed lesional epidermis, with the maximum intensity in the transitional zone. Expression of mRNA of IL-6 receptor showed a similar tendency to that of IL-6. It was expressed in psoriatic epidermis, most strongly in the transitional zone, but not in normal healthy epidermis. IL-6 was demonstrated immunohistochemically in psoriatic epidermis, but IL-6 receptor was demonstrated only in the transitional zone. Thus IL-6 and its receptor expression correlated well with the formation of psoriatic lesions where IL-1 may initiate their expression. IL-6 may play an important role in the pathogenesis of psoriasis.

PubMed Disclaimer

Cited by

Interleukin 6 and 8 levels in plasma and fibroblast cultures in psoriasis.
Zalewska A, Głowacka E, Wyczółkowska J, Tchórzewski H, Narbutt J, Sysa-Jedrzejowska A. Zalewska A, et al. Mediators Inflamm. 2006;2006(1):81767. doi: 10.1155/MI/2006/81767. Mediators Inflamm. 2006. PMID: 16864908 Free PMC article.
Pathogenic function of IL-1 beta in psoriasiform skin lesions of flaky skin (fsn/fsn) mice.
Schön M, Behmenburg C, Denzer D, Schön MP. Schön M, et al. Clin Exp Immunol. 2001 Mar;123(3):505-10. doi: 10.1046/j.1365-2249.2001.01421.x. Clin Exp Immunol. 2001. PMID: 11298140 Free PMC article.
Expression of tumor necrosis factor-alpha and interleukin-6 in oral squamous cell carcinoma.
Nakano Y, Kobayashi W, Sugai S, Kimura H, Yagihashi S. Nakano Y, et al. Jpn J Cancer Res. 1999 Aug;90(8):858-66. doi: 10.1111/j.1349-7006.1999.tb00827.x. Jpn J Cancer Res. 1999. PMID: 10543258 Free PMC article.
IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach.
Asadullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audring H, Volk HD, Döcke WD. Asadullah K, et al. J Clin Invest. 1998 Feb 15;101(4):783-94. doi: 10.1172/JCI1476. J Clin Invest. 1998. PMID: 9466973 Free PMC article. Clinical Trial.
Interleukin 6 receptors on human outer root sheath cells and interfollicular epidermal keratinocytes in vitro: density-induced down regulation (DIDR) of receptors.
Waelti ER, Inaebnit SP, Weismann U, Limat A, Hunziker T. Waelti ER, et al. In Vitro Cell Dev Biol Anim. 1996 May;32(5):255-8. doi: 10.1007/BF02723055. In Vitro Cell Dev Biol Anim. 1996. PMID: 8792152 No abstract available.

References

1. Nucleic Acids Res. 1985 Aug 26;13(16):5869-82 - PubMed
1. J Clin Invest. 1985 Oct;76(4):1585-91 - PubMed
1. Ann N Y Acad Sci. 1989;557:405-14 - PubMed
1. Proc Natl Acad Sci U S A. 1987 Apr;84(7):1940-4 - PubMed
1. Nature. 1986 Nov 6-12;324(6092):73-6 - PubMed

In situ expression of messenger RNA of interleukin-1 and interleukin-6 in psoriasis: interleukin-6 involved in formation of psoriatic lesions - PubMed (original) (raw)